Meta-analysis of 17 cohorts (1,472 patients) with head and neck squamous cell carcinoma on immune checkpoint inhibitors: high tumour mutational burden was associated with better response (OR 2.80), overall survival (HR 0.58) and progression-free survival (HR 0.66).
Meta-analysisn = 1,472
Wang et al. Tissue and Blood-Based Tumor Mutational Burden Predicts Treatment Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis